TY - JOUR T1 - Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy JF - Anticancer Research JO - Anticancer Res SP - 2053 LP - 2058 DO - 10.21873/anticanres.14974 VL - 41 IS - 4 AU - MARTIN SVATON AU - JIRI BLAZEK AU - GABRIELA KRAKOROVA AU - MILOS PESEK AU - MARCELA BURESOVA AU - ZUZANA TEUFELOVA AU - JOSEF VODICKA AU - KAROLINA HURDALKOVA AU - MAGDA BARINOVA AU - ONDREJ TOPOLCAN Y1 - 2021/04/01 UR - http://ar.iiarjournals.org/content/41/4/2053.abstract N2 - Aim: To investigate potential associations between selected oncomarkers [carcinoembryonic antigen (CEA), C-terminus of cytokeratin 19 (CYFRA 21-1, CYFRA), and squamous cell carcinoma antigen (SCC)] and outcomes in patients with NSCLC treated with bevacizumab plus chemotherapy. Patients and Methods: We retrospectively analysed 105 patients with NSCLC from the Czech TULUNG registry treated at University Hospital in Pilsen with bevacizumab plus chemotherapy. Response to therapy was tested by Fisher’s exact test. Survival statistics were evaluated using the Kaplan–Meier method and Cox analysis. Results: Only normal values of CYFRA (not CEA or SCC) were associated with significantly better overall and progression-free survival in univariate analysis. We also observed a trend for a better disease control rate in patients with normal levels of CYFRA. In a multivariate Cox model, only CYFRA was associated with significantly better overall but not progression-free survival. Conclusion: In our retrospective study, we point out the possibility of using CYFRA as a prognostic marker in patients with NSCLC treated with chemotherapy plus bevacizumab. ER -